Related Experiment Video
Updated: Dec 7, 2025
09:06
Manipulation of Epileptiform Electrocorticograms ECoGs and Sleep in Rats and Mice by Acupuncture
Published on: December 22, 2016
9.9K
[Advances in sleep-related hypermotor epilepsy]
Jiahui Xu1, Bo Jin2, Lisan Zhang1
1Department of Neurology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China.
Summary
Sleep-related hypermotor epilepsy (SHE) involves seizures during sleep. Early diagnosis and treatment with medication or surgery are key for managing this rare epilepsy syndrome.
Area of Science:
- Neurology
- Sleep Medicine
- Epileptology
Background:
- Sleep-related hypermotor epilepsy (SHE), previously nocturnal frontal epilepsy, presents with distinct nocturnal seizures.
- Differentiating SHE from parasomnias can be diagnostically challenging.
- The exact incidence of SHE is unknown but considered low.
Purpose of the Study:
- To provide a comprehensive overview of SHE.
- To highlight diagnostic challenges and etiologies.
- To discuss current and potential treatment strategies and prognosis.
Main Methods:
- This review synthesizes existing literature on SHE.
- It focuses on diagnosis, pathogenesis, treatment, and prognosis.
- Emphasis is placed on differentiating SHE from similar sleep disorders.
Main Results:
- SHE seizures are typically asymmetrical, hypermotor, and occur during sleep.
- Etiologies are often unknown, though structural abnormalities play a role.
- Carbamazepine is a primary pharmacological treatment; surgery offers good outcomes for drug-resistant cases.
Conclusions:
- Early and accurate diagnosis of SHE is crucial.
- Understanding the pathogenesis aids in developing targeted treatments.
- Multimodal treatment approaches, including pharmacotherapy and surgery, improve patient outcomes.
Related Concept Videos
01:24Epilepsy and Seizures: Overview
993
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
993
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
671
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
671
01:20Antiepileptic Drugs: Potassium Channel Activators
488
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
488